Satoshi Kobayashi

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Liver Metastases

Clinical Practice

Epidermal Growth Factor Receptor

Top Venues

Liver international : official journal of the International Association for the Study of the Liver

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Manabu Morimoto, Shin Maeda
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver (2024)
Yasuyuki Kawamoto, Chigusa Morizane, Yoshito Komatsu, Shunsuke Kondo, Makoto Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, Daisuke Sakai, Masafumi Ikeda, Hiroshi Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England) (2024)
Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Manabu Morimoto, Shin Maeda
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver 44 (6) (2024)
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese journal of clinical oncology (2024)
Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Manabu Morimoto, Shin Maeda
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver 44 (6) (2024)
Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura, Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Yasuyuki Kawamoto, Chigusa Morizane, Yoshito Komatsu, Shunsuke Kondo, Makoto Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, Daisuke Sakai, Masafumi Ikeda, Hiroshi Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England) (2024)
Taito Fukushima, Manabu Morimoto, Satoshi Kobayashi, Makoto Ueno, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Tatehiro Kagawa, Nobuhiro Hattori, Hiroki Ikeda, Tsunamasa Watanabe, Katsuaki Tanaka, Shin Maeda
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. The oncologist (2023)
Naohiro Okano, Chigusa Morizane, Takuji Okusaka, Ryo Sadachi, Tomoko Kataoka, Satoshi Kobayashi, Masafumi Ikeda, Masato Ozaka, Tomonori Mizutani, Kazuya Sugimori, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Tomohisa Yamamoto, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Kunihito Gotoh, Hironori Yamaguchi, Hiroshi Ishii, Akihiro Ohba, Junji Furuse, Makoto Ueno, null null
Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113. The oncologist (2023)
Shuhei Nagashima, Satoshi Kobayashi, Shotaro Tsunoda, Yui Yamachika, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda
Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. International journal of clinical oncology (2023)
Satoshi Kobayashi, Makoto Ueno, Hiroshi Ishii, Junji Furuse
Management of elderly patients with unresectable pancreatic cancer. Japanese journal of clinical oncology 52 (9) (2022)
Shiro Koizume, Satoshi Kobayashi, Wolfram Ruf, Yohei Miyagi
Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer science 113 (5) (2022)
Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Naohiro Okano, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Hiroshi Imaoka, Tatsuya Yamashita, Haruo Miwa, Hiroaki Nagano, Shiho Arima, Hideyuki Hayashi, Atsushi Naganuma, Hironori Yamaguchi, Terumasa Hisano, Kumiko Umemoto, Shuji Ishii, Koji Nakashima, Rei Suzuki, Yohei Kitano, Toshihiro Misumi, Junji Furuse, Hiroshi Ishii
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. The oncologist 27 (10) (2022)
Makoto Chuma, Haruki Uojima, Nobuhiro Hattori, Yoshitaka Arase, Taito Fukushima, Shunji Hirose, Satoshi Kobayashi, Makoto Ueno, Shun Tezuka, Shuichiro Iwasaki, Naohisa Wada, Kousuke Kubota, Kota Tsuruya, Yoshimasa Shimma, Ikeda Hiroki, Ehira Takuya, Chikako Tokoro, Shigeru Iwase, Yuki Miura, Satoshi Moriya, Tsunamasa Watanabe, Hisashi Hidaka, Manabu Morimoto, Kazushi Numata, Chika Kusano, Tatehiro Kagawa, Shin Maeda
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology research : the official journal of the Japan Society of Hepatology (2021)
Satoshi Kobayashi, Shiro Koizume, Tomoko Takahashi, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Taito Fukushima, Shun Tezuka, Manabu Morimoto, Sho Nakamura, Hiroto Narimatsu, Wolfram Ruf, Yohei Miyagi
Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer science 112 (11) (2021)
Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigusa Morizane, Nobumasa Mizuno, Masafumi Ikeda, Makoto Ueno, Junji Furuse
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer science 109 (8) (2018)
Hiromichi Shirasu, Akiko Todaka, Katsuhiro Omae, Hirofumi Fujii, Nobumasa Mizuno, Masato Ozaka, Hideki Ueno, Satoshi Kobayashi, Kazuhiro Uesugi, Noritoshi Kobayashi, Hideyuki Hayashi, Kentaro Sudo, Naohiro Okano, Yosuke Horita, Keiko Kamei, Seigo Yukisawa, Marina Kobayashi, Akira Fukutomi
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer science 110 (2) (2018)
Satoshi Kobayashi, Makoto Ueno, Kazuya Sugimori, Chigusa Morizane, Yasushi Kojima, Kuniyasu Irie, Yoshihiro Goda, Manabu Morimoto, Shinichi Ohkawa
Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. Cancer chemotherapy and pharmacology 80 (6) (2017)